TETHIC

Tethic is a Finnish biotechnology company focused on developing a novel class of peptide-based therapeutics using its proprietary Tethic platform. The company's technology enables the creation of highly stable and specific peptides designed to address challenging intracellular targets in oncology and immunology. Tethic's primary focus is on the development of peptide-drug conjugates (PDCs) that offer improved precision and reduced toxicity compared to traditional therapies. Currently in the pre-clinical stage, the company is leveraging its platform to build a pipeline of candidates for solid tumors and autoimmune disorders. Tethic was founded as a spin-off from the University of Helsinki and is backed by prominent Nordic investors such as Lifeline Ventures and Tesi.